Hydromorphone Quintian (Hydromorphone Hydrochloride)

Hydromorphone binds to µ‑opioid receptors in the brain and spinal cord, activating inhibitory pathways that reduce the release of pain‑transmitting neurotransmitters, thereby producing strong analgesia and a degree of sedation.

The dose of Hydromorphone Quintian is individualized by the prescribing clinician based on the severity of pain, patient opioid tolerance, and clinical response. No standard dosing regimen is provided here.

Safety data for hydromorphone during pregnancy and lactation are limited. Because opioids can affect the fetus and infant, the drug is generally avoided unless the potential benefit justifies the potential risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Hydromorphone is roughly five to seven times more potent than morphine on a milligram‑per‑milligram basis, offering comparable analgesia with a smaller volume of drug. Both share similar opioid‑related side‑effect profiles, but hydromorphone may have a slightly faster onset when given intravenously.

Store the product at ambient temperature, below 25 °C, in its original container. Protect it from direct light, moisture and extreme temperatures. Keep the vial sealed until use and follow standard aseptic techniques for injectable medications.

Hydromorphone Quintian is supplied as a sterile solution for injection. It is administered intravenously by a qualified healthcare professional, typically as a slow push or infusion, according to the prescriber’s instructions and institutional protocols.

The most critical risks include respiratory depression, severe hypotension, profound sedation, and the potential for dependence, addiction, or overdose. Immediate medical attention is required if signs of respiratory compromise or anaphylaxis occur.

Patients with known hypersensitivity to hydromorphone or any component of the formulation, those with severe respiratory insufficiency, acute or severe bronchial asthma, and individuals taking monoamine oxidase inhibitors within 14 days should avoid this medication.